Manufacturer
SM PHARMACEUTICALS SDN. BHD.
Contents
Ranitidine
Indication
Hypersecretory conditions, Prophylaxis of gastrointestinal haemorrhage from stress ulceration, Benign gastric and duodenal ulceration, Prophylaxis of acid aspiration during general anaesthesia
Instruction
Administer via IV/IM injection by healthcare provider.
Intermittent bolus injection: Dilute 50 mg in 0.9% NaCl or other compatible IV solution to a max concentration of 2.5 mg/mL (20 mL). Intermittent IV infusion: Dilute 50 mg in dextrose 5% or other compatible IV solution to a max concentration of 0.5 mg/mL (100 mL).
Drug interaction
Altered prothrombin time and increased serum concentration with coumarin anticoagulants (e.g. warfarin). May reduce the excretion and increase plasma concentrations of procainamide and N-acetylprocainamide (high dose ranitidine). May alter the absorption of pH-dependent drugs which may result in either an increase in absorption (e.g. triazolam, glipizide, midazolam) or decrease in absorption (e.g. atazanavir, gefitnib, ketoconazole, delaviridine). Decreased absorption with co-administration of high dose sucralfate.
Malaysia
